Aurobindo Pharma Limited
AUROPHARMA
Peringkat dalam Saham
#2093
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures,... Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Harga Saham
$16.95
Kapitalisasi Pasar
$9.75B
Perubahan (1 hari)
-2.26%
Perubahan (1 tahun)
35.57%
Negara
IN
Perdagangan Aurobindo Pharma Limited (AUROPHARMA)
Kategori
Healthcare
Pendapatan untuk Aurobindo Pharma Limited (AUROPHARMA)
Pendapatan pada Jun 2026 TTM: $3.85B
Menurut laporan keuangan terbaru dari Aurobindo Pharma Limited, pendapatan saat ini (TTM) adalah $3.85B. Pada tahun 2025, perusahaan menghasilkan pendapatan sebesar $3.71B peningkatan dibandingkan pendapatan pada tahun 2024 yang sebesar $3.48B. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Aurobindo Pharma Limited dari 2004 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $3.85B | 3.81% |
| 2025 | $3.71B | 6.64% |
| 2024 | $3.48B | 15.00% |
| 2023 | $3.02B | -2.12% |
| 2022 | $3.09B | -8.70% |
| 2021 | $3.38B | 10.38% |
| 2020 | $3.07B | 8.83% |
| 2019 | $2.82B | 11.42% |
| 2018 | $2.53B | 9.80% |
| 2017 | $2.30B | 10.42% |
| 2016 | $2.09B | 7.24% |
| 2015 | $1.94B | -3.94% |
| 2014 | $2.02B | 87.34% |
| 2013 | $1.08B | 20.74% |
| 2012 | $894.99M | -8.97% |
| 2011 | $983.16M | 23.50% |
| 2010 | $796.09M | 31.34% |
| 2009 | $606.15M | -0.42% |
| 2008 | $608.73M | 24.30% |
| 2007 | $489.74M | 36.87% |
| 2006 | $357.80M | 18.22% |
| 2005 | $302.66M | -12.68% |
| 2004 | $346.60M | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 71.71% |
IN
|
